Page 209 - product-manual
P. 209

TM/MC  TM/MC
             PHARMACOLOGICAL ACTIVITIES - TOXICOLOGY - DRUG INTERACTIONS





                               Inositol (C H O )
                                            6  12  6
                               Inositol and its isomers function as the basis for a number of signalling and secondary messenger
                               molecules.  They  are  involved  in  a  number  of  biological  processes,  including  insulin  signal
                               transduction (Larner, 2002), nerve transmission, intracellular calcium  concentration  control
                               (Gerasimenko  et al.,  2006),  metabolism  of  fats  and  reducing  blood  cholesterol  (Rapiejko  et
                               al.,  1986),  cell  membrane  potential  maintenance  (Kukuljan  et al., 1997), serotonin activity
                               modulation (Einat et al., 2001), and gene expression, (Shen et al., 2003; Steger et al., 2003). No
                               deficiencies of inositol have been documented in either dogs or cats (NRC, 2006).



            TOXICOLOGY  Toxicity for inositol has not been documented in dogs and cats when administered orally in therapeutic doses.


                 Oral LD  for inositol is 10 g/kg of body weight in mice (Sciencelab, 2010b).
                        50





                   DRUG    Validated interactions studies do not exist for inositol preparations. Clinical interactions with other
          INTERACTIONS     drugs have not been reported.







        Lecithin

        Lecithin is a generic term to designate any group of yellow-brownish fatty substances occurring
        in animal and plant tissues, and in egg yolk, composed of phosphoric acid, choline, fatty acids,
        glycerol,  glycolipids, triglycerides, and phospholipids. Phosphatidylcholine  occurs in all
        cellular organisms, being one of the major components of the phospholipid portion of the cell
        membrane. Lecithin supplementation decreases hyperlipidemia, influences lipid metabolism,
        exhibits  hepatoprotective  (Lamireau  et  al., 2007) and  immunomodulatory  (Miranda  et  al.,
        2008) effects.



            TOXICOLOGY  Toxicity for lecithin has not been documented in dogs and cats when administered orally in therapeutic doses.


                 Oral LD  for lecithin is >8 ml/kg of body weight in rats (Pfizer, 2009).
                        50




                        DRUG     Validated interactions studies do not exist for lecithin preparations. Clinical interactions with
               INTERACTIONS      other drugs have not been reported.






        24 |   VimForte -VM TM
   204   205   206   207   208   209   210   211   212   213   214